Gliomas | Metastases | ||||||
---|---|---|---|---|---|---|---|
MEP decline | new deficits | temp | perm | new deficits | temp | perm | |
MEP decline >50 % | stable | 4/9 (44.4 %) | 3 (33.3 %) | 1 (11.1 %/1B) | 0/7 (0.0 %) | 0 | 0 |
reversible | 19/85 (22.4 %) | 14 (16.5 %) | 5 (5.9 %/4B, 1I) | 7/32 (21.8 %) | 5 (17.2 %) | 2 (6.9 %/1B,1 I) | |
irreversible | 10/11 | 2 (18.2 %) | 8 (72.7 %) | 3/14 | 0 | 3 (21.4 %) | |
false positive | 1 | - | - | 11 | - | - | |
MEP decline >80 % | stable | 5/24 (20.9 %) | 4 (16.7 %) | 1(4.1 %/1I) | 4/30 (14.0 %) | 2 (6.7 %) | 2 (6.7 %/1B,1 I) |
reversible | 18/70 (25.7 %) | 13 (18.6 %) | 5 (7.1 %/4B, 1I) | 4/20 (20.0 %) | 3 (15 %) | 1 (5.0 %/1B) | |
irreversible | 10/11 (90.9 %) | 2 (18.2 %) | 8 (72.7 %) | 3/3 (100 %) | - | 2 (66.7 %/1U) | |
false positive | 1 | - | - | 1 | - | - |